(2022), which analyzed a broader NSCLC population and demonstrated consistent OS and PFS benefits across PD-L1 subgroups, our findings align in confirming the robust efficacy of ICI plus chemotherapy but also expand upon their work by including additional trials and updated evidence (65). The gene discussed is CD274; the disease is non-small cell lung carcinoma.